Mass Spectrometry - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The mass spectrometry market size is projected to expand from USD 7.16 billion in 2025 and USD 7.64 billion in 2026 to USD 10.56 billion by 2031, registering a CAGR of 6.68% between 2026 to 2031. This report is Segmented by Technology (Hybrid, Single, and More), Component (Instruments, and More), Application (Pharmaceutical & Biotechnology, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). Market Forecasts are Provided in Terms of Value (USD).

Global Mass Spectrometry Market Trends and Insights

Expanding Biopharmaceutical Pipeline Complexity

Antibody-drug conjugates, bispecifics, and cell therapies exceed 40% of the FDA’s active IND docket, and each class demands orthogonal mass spectrometry for intact-mass verification, linker stability, and glycoform mapping. NIH raised its structural-biology and proteomics budget to USD 2.1 billion in fiscal 2025, earmarking funds for Orbitrap and Q-TOF systems to resolve post-translational modifications at single-amino-acid resolution. Contract manufacturers in India and China are installing hybrid quadrupole-time-of-flight platforms to meet Western filing requirements that prioritize mass-based identity testing over legacy chromatographic retention-time checks. Thermo Fisher recorded a 22% rise in Orbitrap shipments to Asia-Pacific biopharma clients during 2025, underscoring the regional pivot toward high-resolution analysis. The shift boosts service revenue as users lock into multi-year maintenance contracts to guarantee 95% uptime.

Stringent Global Food Safety Regulations

The European Union expanded its Maximum Residue Level database to 1,100 pesticide-crop pairs in 2025, obliging food-testing labs to validate each pairing with accredited reference materials. Triple-quadrupole LC-MS/MS dominates because it discerns isobaric pesticides such as chlorpyrifos and chlorpyrifos-methyl in fatty matrices. Japan adopted parallel multi-residue rules in 2024, triggering a 30% jump in LC-MS/MS tenders within 12 months. Brazil followed with mandatory isotope-dilution testing for aflatoxins on all corn exports to the EU starting September 2025. These mandates create a replacement cycle that overrides remaining instrument life, forcing upgrades even for systems purchased after 2020.

High Capital and Operating Costs

A fully configured LC-MS/MS platform with autosampler and compliance software costs nearly USD 400,000, and users budget another USD 60,000 per year for service and consumables. Leasing programs introduced in 2024 trim upfront cash by 40% yet still leave lessees covering maintenance, which represents 70% of total cost of ownership over five years. Fourier-transform instruments draw 15 kW continuously, costing USD 18,000 per year in electricity at industrial rates, an issue for labs facing unstable grids or high tariffs. EU and Japanese regulators mandate full revalidation when ownership changes, eroding the appeal of refurbished instruments.

Other drivers and restraints analyzed in the detailed report include:

• Rising Multi-Omics Research Funding
• Increasing Environmental Monitoring Mandates
• Shortage of Skilled Mass Spectrometry Personnel

Segment Analysis

MALDI-TOF platforms are projected to grow 8.54% annually through 2031, outstripping the broader 6.68% rate as hospital microbiology labs adopt the technology for same-day bacterial and fungal ID. The Bruker MALDI Biotyper, FDA-cleared in 2024 for direct-from-blood-cultur workflows, cuts time-to-result from 48 hours to under 30 minutes, saving USD 3,500 per sepsis case. Hybrid triple-quadrupole LC-MS/MS systems, anchoring 46.65% of 2025 revenue, dominate pharmaceutical QC and multi-residue pesticide testing thanks to unrivaled targeted quantitation. Quadrupole-time-of-flight analyzers are carving space in proteomics for data-independent acquisition, while Orbitrap and FT-ICR remain gold standards for resolving power-intensive tasks despite a modest 12% revenue share. Single-analyzer instruments, once mainstays of teaching labs, are losing ground as hybrid price points fall. ICP-MS demand is accelerating in semiconductor fabs that need to detect metal contaminants at levels below 1 ppb.

Broader technology adoption trends are reshaping the mass spectrometry market. Vendors now market firmware-upgradable platforms that add acquisition modes without hardware swaps, prolonging instrument life and reducing electronic waste. The mass spectrometry market for technology segments is tilting toward systems with embedded ion mobility to decouple isobaric species in complex matrices. Hybrid platforms captured 46.65% of the 2025 mass spectrometry market share, reflecting buyers’ preference for flexibility over single-purpose designs. As regulatory limits tighten, sales of high-resolution, accurate-mass platforms are forecast to reach USD 4.9 billion by 2031, with an 8.1% CAGR led by Orbitrap and Q-TOF. Meanwhile, portable systems priced under USD 100,000 are finding traction in security screening and field environmental testing, opening a secondary upgrade path for legacy benchtops.

Complete Report Scope:

• By Technology
  • Hybrid Mass Spectrometry
    • Triple Quadrupole (LC-MS/MS)
    • Quadrupole Time-of-Flight (Q-TOF)
    • Fourier-Transform (FT-MS)
  • Single Mass Spectrometry
    • Quadrupole
    • Time-of-Flight (TOF)
    • Ion Trap
  • MALDI-TOF Mass Spectrometry
  • Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
  • Other Technologies
• By Component
  • Instruments
  • Ionisation Sources
  • Detectors & Analysers
  • Software & Informatics
  • Services
• By Application
  • Pharmaceutical & Biotechnology
  • Clinical Diagnostics & Proteomics
  • Food & Beverage Testing
  • Environmental Testing
  • Chemical & Petrochemical
  • Forensic & Toxicology
  • Academia & Research Institutes
  • Other Applications
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounts for 42.65% of 2025 revenue, driven by concentrated pharmaceutical R&D, stringent FDA guidance on MS method validation, and early adoption of environmental testing. The EPA’s PFAS rule alone is expected to drive USD 400 million in instrument sales to state and municipal labs between 2025 and 2027. Canada invested CAD 90 million (USD 66 million) in high-throughput proteomics at UBC, positioning it as a multi-omics hub. Mexico’s expansion in biologics contract manufacturing added 12 facilities in 2024-2025, each ordering multiple LC-MS/MS systems.

Asia-Pacific is the fastest-growing region at 7.54% CAGR through 2031. China’s regulator approved 22 biosimilars in 2025, each requiring mass-spectrometry comparability dossiers, fuelling platform demand. India’s API exports hit USD 28 billion in fiscal 2025, up 19% year on year, with ICP-MS and LC-MS/MS central to impurity profiling. Japan expanded reimbursement for MS-based vitamin-D testing in April 2025, adding 2 million annual assays, while South Korea’s chip fabs deployed ICP-MS for ultrapure-water control at sub-3 nm nodes.

Europe accounted for 28% of 2025 revenue. The Green Deal’s 55% emissions-cut goal is catalyzing VOC and PM composition monitoring using high-resolution MS. The UK expanded its newborn screening panel to 35 disorders in 2024, prompting 14 regional labs to upgrade to tandem-MS platforms. Middle East & Africa, with 6% share, grows 6.9% as GCC states expand food-safety labs, while South America’s 6.2% growth rests on Brazil’s environmental mandates and Argentina’s pharma exports, although currency swings limit capex.

List of Companies Covered in this Report:

• Advion Inc.
• Agilent Technologies
• Analytik Jena GmbH
• Bio-Rad Laboratories
• Bruker
• Danaher
• Exum Instruments
• Hitachi
• Hiden Analytical Ltd.
• JEOL Ltd.
• Kore Technology Ltd.
• LECO
• MKS Instruments (Extrel)
• PerkinElmer
• Rigaku
• Shimadzu
• Thermo Fisher Scientific
• TOFWERK AG
• Trajan Scientific And Medical
• Waters Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support